CUE - Downdtrend Breakout & Upcoming Catalysts
Updated
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Disclaimer: This content is for informational purposes only and is not intended as financial advice.
Upcoming Catalyst:
Date: 23/05/2024
Details: Expecting a pre-run-up into the data release.
Investment Overview (Dated 03/05/2024):
Relative Volume: 2.35
Shares Float: 47.07 million
Short Float: 10.15%
Financial Health:
Cue Health Inc. (HLTH) has a debt-to-equity ratio of 0.19, showing relatively low debt compared to equity.
A current ratio of 2.54 and a quick ratio of 1.91 indicate sufficient liquidity for short-term obligations.
Key Technical Levels:
Resistance Levels: Watch for resistance at $2.50, $2.75, $3.60, and $4.40. Breaking above these thresholds could indicate upward movement, where taking partial profits may secure gains.
Trading Strategy:
Take Profit (TP): Aim for a profit target at around $6.80 for maximum returns.
Stop Loss (SL): Place a stop loss below $1.50 to limit potential losses.
Chart Analysis:
Refer to the accompanying chart for a detailed visual analysis of price movements and trend lines.
Trading Caution:
Trade with careful consideration of market conditions and personal risk tolerance.
Conduct thorough research or consult a financial advisor before making investment decisions.
Disclaimer: This content is for informational purposes only and is not intended as financial advice.
Upcoming Catalyst:
Date: 23/05/2024
Details: Expecting a pre-run-up into the data release.
Investment Overview (Dated 03/05/2024):
Relative Volume: 2.35
Shares Float: 47.07 million
Short Float: 10.15%
Financial Health:
Cue Health Inc. (HLTH) has a debt-to-equity ratio of 0.19, showing relatively low debt compared to equity.
A current ratio of 2.54 and a quick ratio of 1.91 indicate sufficient liquidity for short-term obligations.
Key Technical Levels:
Resistance Levels: Watch for resistance at $2.50, $2.75, $3.60, and $4.40. Breaking above these thresholds could indicate upward movement, where taking partial profits may secure gains.
Trading Strategy:
Take Profit (TP): Aim for a profit target at around $6.80 for maximum returns.
Stop Loss (SL): Place a stop loss below $1.50 to limit potential losses.
Chart Analysis:
Refer to the accompanying chart for a detailed visual analysis of price movements and trend lines.
Trading Caution:
Trade with careful consideration of market conditions and personal risk tolerance.
Conduct thorough research or consult a financial advisor before making investment decisions.
Comment
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. CUE
, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will take part in a fireside chat at The Citizens JMP Life Sciences Conference being held in New York, May 13-14, 2024.
During the fireside chat, Cue Biopharma will discuss current oncology and autoimmune disease strategies and progress.
Presentation Details
The Citizens JMP Life Sciences Conference
Date and Time: Tuesday, May 14 2024, 12:00 – 12:25 p.m. ET
Webcast Link: wsw.com/webcast/jmp63/cue/1530576
Presenter: Daniel Passeri, chief executive officer, Cue Biopharma
Trade closed: stop reached
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.